BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1101 related articles for article (PubMed ID: 26756400)

  • 1. Cellular and molecular modifier pathways in tauopathies: the big picture from screening invertebrate models.
    Hannan SB; Dräger NM; Rasse TM; Voigt A; Jahn TR
    J Neurochem; 2016 Apr; 137(1):12-25. PubMed ID: 26756400
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cytoskeleton proteins are modulators of mutant tau-induced neurodegeneration in Drosophila.
    Blard O; Feuillette S; Bou J; Chaumette B; Frébourg T; Campion D; Lecourtois M
    Hum Mol Genet; 2007 Mar; 16(5):555-66. PubMed ID: 17309878
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impaired retrograde transport by the Dynein/Dynactin complex contributes to Tau-induced toxicity.
    Butzlaff M; Hannan SB; Karsten P; Lenz S; Ng J; Voßfeldt H; Prüßing K; Pflanz R; Schulz JB; Rasse T; Voigt A
    Hum Mol Genet; 2015 Jul; 24(13):3623-37. PubMed ID: 25794683
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Drosophila models of human tauopathies indicate that Tau protein toxicity in vivo is mediated by soluble cytosolic phosphorylated forms of the protein.
    Feuillette S; Miguel L; Frébourg T; Campion D; Lecourtois M
    J Neurochem; 2010 May; 113(4):895-903. PubMed ID: 20193038
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Neurodegeneration and defective neurotransmission in a Caenorhabditis elegans model of tauopathy.
    Kraemer BC; Zhang B; Leverenz JB; Thomas JH; Trojanowski JQ; Schellenberg GD
    Proc Natl Acad Sci U S A; 2003 Aug; 100(17):9980-5. PubMed ID: 12872001
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Transgenic animal models of tauopathies.
    Lee VM; Kenyon TK; Trojanowski JQ
    Biochim Biophys Acta; 2005 Jan; 1739(2-3):251-9. PubMed ID: 15615643
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Important neuronal toxicity of microtubule-bound Tau in vivo in Drosophila.
    Talmat-Amar Y; Arribat Y; Redt-Clouet C; Feuillette S; Bougé AL; Lecourtois M; Parmentier ML
    Hum Mol Genet; 2011 Oct; 20(19):3738-45. PubMed ID: 21705366
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeted Downregulation of dMyc Suppresses Pathogenesis of Human Neuronal Tauopathies in Drosophila by Limiting Heterochromatin Relaxation and Tau Hyperphosphorylation.
    Chanu SI; Sarkar S
    Mol Neurobiol; 2017 May; 54(4):2706-2719. PubMed ID: 27000837
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Conserved Cytoskeletal Signaling Cascade Mediates Neurotoxicity of FTDP-17 Tau Mutations
    Bardai FH; Wang L; Mutreja Y; Yenjerla M; Gamblin TC; Feany MB
    J Neurosci; 2018 Jan; 38(1):108-119. PubMed ID: 29138281
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tau alteration and neuronal degeneration in tauopathies: mechanisms and models.
    Brandt R; Hundelt M; Shahani N
    Biochim Biophys Acta; 2005 Jan; 1739(2-3):331-54. PubMed ID: 15615650
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Molecular pathways that influence human tau-induced pathology in Caenorhabditis elegans.
    Kraemer BC; Burgess JK; Chen JH; Thomas JH; Schellenberg GD
    Hum Mol Genet; 2006 May; 15(9):1483-96. PubMed ID: 16600994
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Transgenic zebrafish as a novel animal model to study tauopathies and other neurodegenerative disorders in vivo.
    Paquet D; Schmid B; Haass C
    Neurodegener Dis; 2010; 7(1-3):99-102. PubMed ID: 20173336
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Kinesin-1 transport reductions enhance human tau hyperphosphorylation, aggregation and neurodegeneration in animal models of tauopathies.
    Falzone TL; Gunawardena S; McCleary D; Reis GF; Goldstein LS
    Hum Mol Genet; 2010 Nov; 19(22):4399-408. PubMed ID: 20817925
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Filamin-A and Myosin VI colocalize with fibrillary Tau protein in Alzheimer's disease and FTDP-17 brains.
    Feuillette S; Deramecourt V; Laquerriere A; Duyckaerts C; Delisle MB; Maurage CA; Blum D; Buée L; Frébourg T; Campion D; Lecourtois M
    Brain Res; 2010 Jul; 1345():182-9. PubMed ID: 20460118
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibition of tau aggregation in a novel Caenorhabditis elegans model of tauopathy mitigates proteotoxicity.
    Fatouros C; Pir GJ; Biernat J; Koushika SP; Mandelkow E; Mandelkow EM; Schmidt E; Baumeister R
    Hum Mol Genet; 2012 Aug; 21(16):3587-603. PubMed ID: 22611162
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Misfolded tau protein and disease modifying pathways in transgenic rodent models of human tauopathies.
    Zilka N; Korenova M; Novak M
    Acta Neuropathol; 2009 Jul; 118(1):71-86. PubMed ID: 19238406
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Brief update on different roles of tau in neurodegeneration.
    Ittner A; Ke YD; van Eersel J; Gladbach A; Götz J; Ittner LM
    IUBMB Life; 2011 Jul; 63(7):495-502. PubMed ID: 21698753
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Transgenic zebrafish model of neurodegeneration.
    Tomasiewicz HG; Flaherty DB; Soria JP; Wood JG
    J Neurosci Res; 2002 Dec; 70(6):734-45. PubMed ID: 12444595
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Animal models of tauopathies].
    Higuchi M
    Rinsho Shinkeigaku; 2006 Nov; 46(11):928-30. PubMed ID: 17432223
    [TBL] [Abstract][Full Text] [Related]  

  • 20. V363I and V363A mutated tau affect aggregation and neuronal dysfunction differently in C. elegans.
    Morelli F; Romeo M; Barzago MM; Bolis M; Mattioni D; Rossi G; Tagliavini F; Bastone A; Salmona M; Diomede L
    Neurobiol Dis; 2018 Sep; 117():226-234. PubMed ID: 29936232
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 56.